Folate receptor-α expression in resectable hepatic colorectal cancer metastases: Patterns and significance

Modern Pathology

Volumn 24, Issue 9, 2011, Pages 1221-1228

  D'Angelica, Michael ^a   Ammori, John ^a   Gonen, Mithat ^a   Klimstra, David S ^a   Low, Philip S ^b   Murphy, Linda ^c   Weiser, Martin R ^a   Paty, Philip B ^a   Fong, Yuman ^a   Dematteo, Ronald P ^a   Allen, Peter ^a   Jarnagin, William R ^a   Shia, Jinru ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b PURDUE UNIVERSITY   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Folate receptor 1 (adult); folate targeted therapy; liver metastasis

Indexed keywords

FOLATE RECEPTOR 1; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN BCL 2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P27; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; FOLATE RECEPTOR 1; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052413192     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.82     Document Type: Article

References (34)

1. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318; discussion 18-21.
2. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of longterm survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008;247:125-135.
3. Abdalla EK, Adam R, Bilchik AJ, et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13: 1271-1280. (Pubitemid 44435793)
4. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-499.
5. Basal E, Eghbali-Fatourechi GZ, Kalli KR, et al. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One 2009;4:e6292.
6. Henderson GB. Folate-binding proteins. Annu Rev Nutr 1990;10:319-335.
7. Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem 2010;53:6811-6824.
8. Kularatne SA, Low PS. Targeting of nanoparticles: folate receptor. Methods Mol Biol 2010;624:249-265.
9. Brown Jones M, Neuper C, Clayton A, et al. Rationale for folate receptor alpha targeted therapy in 'high risk' endometrial carcinomas. Int J Cancer 2008;123: 1699-1703.
10. Hartmann LC, Keeney GL, Lingle WL, et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 2007;121:938-942. (Pubitemid 47101628)
11. Toffoli G, Russo A, Gallo A, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 1998;79:121-126. (Pubitemid 28201681)
12. Iwakiri S, Sonobe M, Nagai S, et al. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol 2008;15:889-899.
13. Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-293. (Pubitemid 40312593)
14. Low PS, Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 2004;56:1055-1058. (Pubitemid 38496506)
15. Lu Y, Sega E, Leamon CP, et al. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev 2004;56: 1161-1176. (Pubitemid 38496513)
16. Leamon CP, Reddy JA, Vlahov IR, et al Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm 2007;4:659-667. (Pubitemid 350004265)
17. Li J, Sausville EA, Klein PJ, et al. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009;49:1467-1476.
18. Reddy JA, Dorton R, Westrick E, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007;67:4434-4442. (Pubitemid 46815093)
19. Siegel BA, Dehdashti F, Mutch DG, et al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003;44:700-707. (Pubitemid 39655203)
20. Naumann RW, Symanowski JT, Ghamande SA, et al. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. Asco Meeting Abstr 2010;28:LBA5012B-LBA5LBAb.
21. Shia J, Klimstra DS, Nitzkorski JR, et al. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol 2008;39:498-505. (Pubitemid 351375020)
22. Moore HG, Shia J, Klimstra DS, et al Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. Ann Surg Oncol 2004;11:955-961. (Pubitemid 40486660)
23. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92:434-444. (Pubitemid 40395523)
24. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-96.
25. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618. (Pubitemid 46224239)
26. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004;22:529-536. (Pubitemid 41079782)
27. Rosati G, Chiacchio R, Reggiardo G, et al. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol 2004;25:258-263. (Pubitemid 40082328)
28. Russo A, Bazan V, Iacopetta B, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005;23: 7518-7528. (Pubitemid 46291815)
29. Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007;104:18654-18659. (Pubitemid 350210752)
30. Shankaran V, Wisinski KB, Mulcahy MF, et al. The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Mol Diagn Ther 2008;12:87-98. (Pubitemid 351570864)
31. Gonen M, Hummer A, Zervoudakis A, et al. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 2003;21:406-412. (Pubitemid 46606467)
32. Lassmann S, Tang L, Capanu M, et al. Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy. Gastroenterology 2007;133:1831-1839. (Pubitemid 350180803)
33. Mikami T, Yoshida T, Numata Y, et al. Low frequency of promoter methylation of O6-methylguanine DNA methyltransferase and hMLH1 in ulcerative colitisassociated tumors: comparison with sporadic colonic tumors. Am J Clin Pathol 2007;127:366-373. (Pubitemid 46806329)
34. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr 2000;130:129-132. (Pubitemid 30073783)